Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study - Paula Rodriguez-Otero; Daniel Morillo; Anita D'Souza; Donna Reece; Niels van de Donk; Ajai Chari; Bhagirathbhai Dholaria; K. Martin Kortüm; Maria-Victoria Mateos; John T. Mckay; Laura Rosiñol; Anna Sureda; et al. (Blood Advances, 2026)